Skip to main content

Table 1 Demographics and clinical characteristics

From: Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis

  Nonactive disease Active disease Total
Patients 14 60 74
Age (years) 37.5 (26.2 to 37.5) 34.0 (28.0 to 40.0) 35.0 (27.5 to 42.0)
Female/male 11/3 52/8 63/11
Race: African American, Hispanic, White 7, 7, 0 26, 27, 7 33, 34, 7
SLEDAI 2 (0 to 5.25) 10 (4 to 17) 10 (4 to 16)
Renal SLEDAI 0 8 (4 to 8) 4 (4 to 8)
Renal pathology    
World Health Organization classification   
   II 4 8 12
   III 1 16 17
   IV 3 25 28
   V 6 7 13
   Unknown 0 3 3
Protein:creatinine ratio 0.190 ± 0.040 1.536 ± 0.229* 1.278 ± 0.195
Serum creatinine 1.422 ± 0.403 1.738 ± 0.191 1.677 ± 0.172
Positive anti-dsDNA (total tested) 4 (11) 30 (50) 34 (61)
Hypocomplementemia (total tested) 9 (11) 35 (46) 44 (57)
Current medications    
   Prednisone 10 47 57
   Mycophenolic acid 5 24 29
   Cyclophosphamide 0 3 3
   Azathioprine 2 3 5
   Methotrexate 1 1 2
   Cyclosporin A 0 1 1
   Angiotensin blocking agents 9 32 41
   Hydrochloroquine 7 26 33
  1. Data presented as n, median (interquartile range) or mean ± standard error. Nonactive disease, renal Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) = 0; active disease, renal SLEDAI > 0. dsDNA, double-stranded DNA. *P < 0.01, active versus nonactive.